A 58-year-old man with rheumatoid arthritis and a history of myocardial infarction 2 years ago requires long-term analgesia. Which feature best distinguishes the safety profile of non-selective NSAIDs from COX-2 selective inhibitors in this patient's context?

Explanation

## COX-2 Inhibitors vs. Non-Selective NSAIDs: Safety Profile Comparison **Key Point:** The most accurate distinguishing feature between non-selective NSAIDs and COX-2 selective inhibitors relevant to this post-MI patient is that **COX-2 inhibitors cause less platelet inhibition** — they do not inhibit COX-1-mediated thromboxane A₂ production in platelets, meaning they lack antiplatelet activity and do not interfere with anticoagulation regimens. ### Mechanism of Platelet Effects | NSAID Class | COX-1 Platelet Effect | Thromboxane A₂ | Platelet Aggregation | |-------------|----------------------|----------------|---------------------| | Non-selective (ibuprofen, naproxen) | Inhibited (reversible) | ↓ | ↓ (antiplatelet effect) | | COX-2 selective (celecoxib, etoricoxib) | Spared | Normal | Unchanged | **High-Yield:** COX-2 inhibitors selectively inhibit COX-2 without affecting COX-1 in platelets. This means they do **not** inhibit platelet aggregation. In patients on anticoagulants or antiplatelet therapy (e.g., aspirin, warfarin, clopidogrel), COX-2 inhibitors do not add to bleeding risk from platelet inhibition — making Option A the most factually accurate distinguishing statement. ### Why the Other Options Are Incorrect - **Option B (original answer):** INCORRECT. Current evidence from the PRECISION trial and multiple meta-analyses shows that non-selective NSAIDs do NOT carry lower cardiovascular thrombotic risk than COX-2 inhibitors. Both classes increase CV thrombotic risk. Non-selective NSAIDs are NOT preferred in post-MI patients for CV protection. The modest antiplatelet effect of COX-1 inhibition is clinically insufficient to confer cardioprotection [Harrison's Principles of Internal Medicine, 21e, Ch. 297; PRECISION Trial, NEJM 2016]. - **Option C:** Partially true (COX-2 inhibitors are GI-safer), but the claim that they "do not increase MI recurrence risk" is factually **false** — COX-2 inhibitors do carry increased cardiovascular thrombotic risk, particularly in patients with established CV disease. - **Option D:** Completely false. Non-selective NSAIDs have significant renal toxicity (reduced prostaglandin-mediated afferent arteriolar dilation → reduced GFR) and are **contraindicated** in elderly patients with reduced GFR [KD Tripathi, Essentials of Medical Pharmacology, 8e]. ### Clinical Pearl for This Patient In a post-MI patient requiring long-term analgesia: - **Both** non-selective NSAIDs and COX-2 inhibitors carry cardiovascular risk and should be used with caution or avoided - COX-2 inhibitors are preferred when GI protection is needed (lower ulcer risk) - Neither class is "safe" from a CV standpoint in post-MI patients - The key pharmacological distinction is **platelet COX-1 sparing** by COX-2 inhibitors **Clinical Pearl:** Per KD Tripathi and Harrison's, the defining pharmacological difference between these classes in the context of anticoagulation/antiplatelet therapy is that COX-2 inhibitors do not inhibit platelet function, making Option A the best factual distinguishing statement among the choices provided.